Licensing Opportunities
KKC is seeking to license several of our technologies in inflammation and infectious disease. Each product opportunity is accompanied by an intellectual property estate as well as lead antibody molecules.
Biodefense Project - Monoclonal Antibody
KKC has developed a panel of fully human monoclonal antibodies that will have applications in preventing/treating an NIAID Category A biodefense target. Initial proof of concept studies have been completed and additional in vitro and in vivo studies are in progress. KKC is offering the fully human monoclonal antibodies for licensing.
Additional information is available under confidentiality.
For additional information on our Licensing Opportunities, or for any other licensing inquiries, please contact the Business Development department at (858) 952-7000 or contact@kyowa-kirin-ca.com.
